Retatrutide vs Exenatide
Side-by-Side Comparison
| Attribute | Retatrutide | Exenatide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / GLP-1 Agonist |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... | Exenatide binds to and activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. |
| Evidence Rating | B — Phase III / NDA Filed | A — FDA Approved |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | FDA-approved (Byetta for T2D, 2005; Bydureon for T2D, 2012) |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common (>=5%): nausea (44% with Byetta, decreases over time), vomiting, diarrhea, dizziness, headache, jitteriness; Injection site reactions more common with Bydureon extended-release (up to 17%) including nodules at injection site |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous injection |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | Byetta: 5-10 mcg BID; Bydureon: 2 mg once weekly |
| Frequency | Once weekly | Twice daily (Byetta) or Once weekly (Bydureon) |
| Molecular Weight | N/A | ~4186.6 g/mol |
| Half-Life | ~6 days (allows once-weekly dosing) | ~2.4 hours (Byetta); ~2 weeks sustained release (Bydureon) |
Overview
Retatrutide and Exenatide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Exenatide — Mechanism & Evidence
Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) originally derived from exendin-4, a peptide found in the saliva of the Gila monster (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA, with Byetta (twice-daily injection) approved in April 2005 and Bydureon (once-weekly extended-release) approved in January 2012, both for type 2 diabetes. Exenatide shares approximately 53% sequence homology with human GLP-1 and is resistant to DPP-4 degradation.
Key claims: Improves glycemic control in type 2 diabetes; Produces modest weight loss; Extended-release formulation provides superior glycemic control.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Exenatide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Exenatide: Common (>=5%): nausea (44% with Byetta, decreases over time), vomiting, diarrhea, dizziness, headache, jitteriness Injection site reactions more common with Bydureon extended-release (up to 17%) including nodules at injection site Hypoglycemia risk increased when combined with sulfonylureas or insulin
Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Related Research News
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Retatrutide Monthly Research Cost in Australia Breakdown
Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.